Ajanta Pharma
Ajanta Pharma is a publicly listed Indian specialty pharmaceutical company manufacturing branded generic and generic formulations across India, 33+ emerging markets, and the USA. It operates 7 manufacturing facilities and 850+ scientist R&D, generating ₹5,453 crore FY26 revenue across cardiology, dermatology, ophthalmology, and other therapeutic segments.
- Company typePublic
- Founded1979
- HeadquartersMumbai, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ajanta Pharma does
Ajanta Pharma Limited is a specialty pharmaceutical company headquartered in Mumbai, India, founded in 1979 and publicly traded on Indian stock exchanges (NSE/BSE) under the ticker AJANTPHARMA. The company develops, manufactures, and markets branded generic and generic finished dosage formulations across three core business segments: India Branded Generics (Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology — 350+ products with over 50% first-to-market, ranked 24th in India per IQVIA March 2026), Emerging Markets Branded Generics (33+ countries across Africa, South-East Asia, Central Asia, and Middle East with 250+ brands), and US Generics through subsidiary Ajanta Pharma USA Inc. (49 commercialized ANDAs plus 19 awaiting FDA approval).
The company's technology foundation is formulation chemistry and complex drug development, supported by 850+ scientists at a 100,000 sq. ft. R&D facility in Mumbai and seven manufacturing facilities in India (six finished formulation facilities plus one captive API plant), with US FDA and WHO GMP approvals at Paithan and Dahej. Notable technical capabilities include extended-release formulations (Met XL — first generic extended-release Metoprolol in India), triple-drug combinations (Rosutor Gold — first combination of Rosuvastatin, Aspirin, and Clopidogrel), and fast-onset ophthalmic formulations (Alcarex — 3-minute vs 15-minute onset).
The business model operates across three revenue streams: India distribution via field sales force through pharmacy and healthcare channels, emerging markets via own dedicated sales teams in each geography, and US market via subsidiary working with major US distributors. FY2025-26 consolidated revenue reached ₹5,453 crore (17% YoY growth) with PAT of ₹1,056 crore (crossing the ₹1,000 crore threshold for the first time) and Adjusted EBITDA of ₹1,498 crore. Recent strategic actions include a December 2025 in-licensing agreement with Biocon to commercialize semaglutide in 26 emerging markets.
Ajanta Pharma firmographics
Firmographics- Name
- Ajanta Pharma
- Legal name
- Ajanta Pharma Limited
- Website
- https://ajantapharma.com
- Company type
- Public
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Ajanta Pharma is a publicly listed Indian specialty pharmaceutical company manufacturing branded generic and generic formulations across India, 33+ emerging markets, and the USA. It operates 7 manufacturing facilities and 850+ scientist R&D, generating ₹5,453 crore FY26 revenue across cardiology, dermatology, ophthalmology, and other therapeutic segments.
- Ownership category
- akta.pro rank
Ajanta Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
Keywords
Where Ajanta Pharma is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices12 records
Markets served
Ajanta Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- India Branded Generics: Revenue from branded generic medicines sold in India across specialty therapeutic segments including Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology. Ranked 24th in India as per IQVIA March 2026.
- Emerging Markets - Branded Generics: Revenue from branded generics in 33+ emerging markets across Africa, South-East Asia, Central Asia and Middle East. Over 250 brands with significant market shares and leadership positions.
- USA Generics: Revenue from generic pharmaceutical products in US market through subsidiary Ajanta Pharma USA Inc. 49 ANDA approvals commercialized with 19 awaiting FDA approval. US Generics segment grew 49% in FY26.
- Semaglutide Partnership: In-licensing agreement with Biocon to market semaglutide in 26 emerging markets across Africa, Middle East, and Central Asia, expected to contribute ₹200 crore in FY28E
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Pharmaceutical products sold through healthcare providers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Ajanta Pharma product offering
Product offeringCore offering
Ajanta Pharma manufactures and markets specialty pharmaceutical finished dosage formulations across three business segments: India Branded Generics (Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, Gynaecology), Emerging Markets Branded Generics in 33+ countries, and USA Generics through subsidiary Ajanta Pharma USA Inc. The company produces 600+ products in multiple dosage forms (tablets, capsules, sterile eye drops, injectables, ointments, creams, oral liquids) from 7 manufacturing facilities, with over 50% of India products being first-to-market.
Product overview
Ajanta Pharma is a specialty pharmaceutical company that operates three distinct business segments: (1) India Branded Generics covering Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, and Gynaecology with 350+ products (50%+ first-to-market) ranking 24th in India; (2) Emerging Markets Branded Generics across 33+ countries in Africa, Asia, and Middle East with 250+ brands; and (3) USA Generics with 49 commercialized ANDAs and 19 awaiting approval. The company manufactures 7 different dosage forms (tablets, capsules, sterile eye drops, injectables, ointments/creams, oral liquids, dry powder suspension) across 7 facilities in India, with US FDA and WHO approved sites at Paithan and Dahej.
Differentiator
Problem solved
Functional benefit
Brands
- Met XL: Flagship anti-hypertensive brand, first generic extended-release formulation of Metoprolol launched in India
- Rosutor Gold
- Alcarex
- Bimat
- Feburic
Products and services
- Met XL
Quantifiable outcome
- Revenue crossed ₹5,000 crore milestone at ₹5,453 crore in FY2025-26
- +4 more outcomes
Companies that use Ajanta Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Ajanta Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ajanta Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BioconcoreAjanta Pharma plans to launch generic semaglutide in Asia and Africa markets through partnership with Biocon, positioning itself in the rapidly growing metabolic therapy market. The collaboration is part of Ajanta's strategy to expand into chronic therapy markets following the patent expiry of semaglutide.
- BioconcoreAjanta Pharma entered into an in-licensing agreement with Biocon to market semaglutide (a GLP-1 receptor agonist for diabetes and weight management) in 26 emerging markets across Africa, Middle East, and Central Asia. Under the agreement, Biocon manufactures and supplies semaglutide while Ajanta handles commercialization in select markets. The deal is expected to generate ₹200 crore in revenue by FY28E with estimated EBITDA margin of 50-55%. Regulatory approvals expected in late 2026 or early 2027.
- BioconcoreBiocon out-licensed its Semaglutide diabetes drug to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in 3 additional countries across Africa, Middle East and Central Asia. This strategic move leverages Ajanta's distribution infrastructure in emerging markets for the rapidly growing GLP-1 market.
Scale indicators19 records
Recent moves5 records
Expansion highlights5 records
Ajanta Pharma competitors and assessment
Company assessmentDirect peers
- Cipla: Indian specialty pharmaceutical manufacturer with comparable India branded-generics, emerging-markets (Africa/Asia) and US generics franchises. Direct overlap in cardiology, respiratory and chronic therapy segments.
- Glenmark Pharmaceuticals: India-headquartered specialty pharma with branded generics in India and emerging markets plus a US generics business. Comparable therapeutic-segment focus and own manufacturing footprint.
- Aurobindo Pharma: Large Indian pharma with deep US generics presence (extensive ANDA portfolio) and growing emerging-markets franchise. Direct overlap in generic finished dosage forms and US distribution.
- Torrent Pharmaceuticals: Indian specialty pharma focused on branded generics in cardiology, dermatology and gastroenterology in India plus emerging markets. Closely aligned therapeutic-segment strategy.
- Alkem Laboratories: Indian specialty pharma with branded generics in India and US generics presence. Direct peer on the India specialty-pharma axis with similar therapeutic-segment breadth.
- Cadila Healthcare (Zydus): Indian pharma with branded generics in India, US generics franchise and emerging-markets operations. Comparable scale, dosage-form breadth and regulatory footprint.
- Ipca Laboratories: Indian specialty pharma with branded generics in India and emerging markets plus US generics. Overlap in dosage forms (tablets, injectables) and chronic-therapy segments.
- Mankind Pharma: Leading Indian branded-generics company with strong domestic sales force. Comparable field-sales-led GTM model and India specialty positioning across multiple therapeutic areas.
- Alembic Pharmaceuticals: Indian pharma with India branded generics and US generics (ANDA) business. Comparable specialty-pharma positioning with India manufacturing and USFDA-approved sites.
- Lupin Limited: Indian specialty pharma with major US generics presence and India/emerging-markets branded-generics. Closely comparable on US ANDA pipeline depth and India specialty portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ajanta Pharma social profiles
Digital presenceAjanta Pharma compliance and trust
Trust signalCompliance2 records
Ajanta Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ajanta Pharma leadership team
Management profileNumber of profiles
Profiles10 records
Ajanta Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
Ajanta Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ajanta Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ajanta Pharma
What does Ajanta Pharma do?
Ajanta Pharma manufactures and markets specialty pharmaceutical finished dosage formulations across three business segments: India Branded Generics (Cardiology, Dermatology, Ophthalmology, Pain Management, Nephrology, Gynaecology), Emerging Markets Branded Generics in 33+ countries, and USA Generics through subsidiary Ajanta Pharma USA Inc. The company produces 600+ products in multiple dosage forms (tablets, capsules, sterile eye drops, injectables, ointments, creams, oral liquids) from 7 manufacturing facilities, with over 50% of India products being first-to-market.
Is Ajanta Pharma a public or private company?
Ajanta Pharma is a public company. It is classified as public and is currently operating.
When was Ajanta Pharma founded?
Ajanta Pharma was founded in 1979. It employs 5,001 to 10,000 people.
Where is Ajanta Pharma based?
Ajanta Pharma is headquartered in Mumbai, India, in the Asia region.
How does Ajanta Pharma make money?
Four revenue lines are on record. India Branded Generics are the primary driver. The others are emerging Markets - Branded Generics, USA Generics and semaglutide Partnership.
Who are Ajanta Pharma's main competitors?
Direct peers on record are Cipla, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Cadila Healthcare (Zydus), Ipca Laboratories, Mankind Pharma, Alembic Pharmaceuticals and Lupin Limited.
Does Ajanta Pharma have an API?
No public API is recorded for Ajanta Pharma.
What industry is Ajanta Pharma in?
Ajanta Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.